We compare, we don't sell.Some links pay us. How we make money
Peptide Chooser
Compare by goal

Are peptides legal in the US? It depends on the kind.

Peptide Chooser editorial team. Checked 2 Nov 2026.

Short answer

It depends on the kind. An FDA-approved peptide medicine is legal on a prescription.1 A pharmacy may make some peptides for a patient under the FDA's compounding rules.2 Cosmetic peptides are legal to sell without approval.3 Research-use peptides are not approved for use in people.4 The FDA warning letters we track went to the companies selling peptides, not to people who bought them.5

What are the four kinds of peptide?

The law treats a peptide by how it is made and sold, not by what it is. The same substance can be an approved medicine in one product and a research-use powder in another.

  • FDA-approved medicines. The maker sent the FDA its trial data, and the FDA found that the benefits outweigh the known risks.1 In our database: Afamelanotide, Bremelanotide and Elamipretide.
  • Pharmacy-made (compounded). A pharmacy makes the medicine for one patient with a prescription. It is not FDA approved, and the FDA does not check its safety, effectiveness or quality before it is sold.6 In our database: Glutathione, NAD+ and Vasoactive intestinal peptide.
  • Cosmetics. Serums and creams with peptides. They do not need FDA approval before they are sold.3 On our legal table: GHK-Cu, Matrixyl, Argireline (creams and serums).
  • Research-use. Powders and vials sold "for research only". They are not approved for use in people.4 In our database: AOD-9604, ARA-290 and BPC-157.

What are the 503A lists?

Section 503A of the federal drug law covers ordinary pharmacies. A pharmacy may make a medicine from a raw ingredient only if that ingredient is allowed, for example because it is on the FDA's 503A bulks list.2

While the FDA reviews the ingredients people have asked to add, it sorts them into three groups:2

  • Category 1: enough information was sent to review it; the FDA does not plan to act against pharmacies that use it, under conditions.
  • Category 2: the FDA found significant safety risks, so the category 1 policy does not apply.
  • Category 3: too little information was sent to review it.

The FDA's page on substances that may be risky to compound also names peptides whose nomination was withdrawn, such as BPC-157.7 Outsourcing facilities work under a different section, 503B, with their own list.8

What does "research use only" mean for a buyer?

It is a label the seller puts on the product: it says the product is for lab research, not for people. It does not make the product approved, checked or safe to use.1 It also does not tell you what is in the vial; only a lab report from an outside lab can, and only for one batch. Our guide on how to read a COA explains what to look for.

The FDA warning letters on our letters page went to companies: 20 of the 172 went to research-use peptide shops.5 We make no claim about what the law means for a person who buys one. A lawyer can answer that for your state.

How do you read our status chip?

Every peptide on our pages carries one chip, taken from our database when it has a row for the substance, else from our own checked table:

  • FDA approved an FDA-approved product with this substance exists. It may be approved for one use and not for another.
  • Pharmacy-made pharmacies may make it while the FDA reviews it; there is no approved product.
  • Not approved no approved product, and the FDA has not allowed pharmacies to use it, or its nomination was withdrawn.
  • Cosmetic sold as a cosmetic; no approval is needed.

Each status on our legal table and our peptide pages comes with its source and the date we first saw it. Our Is it legal today? table and our peptides A to Z show every one.

Can a status change?

Yes. The FDA can add a substance to a list, move it between categories or approve a new product. In July 2026 its compounding advisory committee reviewed BPC-157, TB-500, MOTS-c and epitalon, and the FDA proposed not to allow them.9 We check the FDA's pages and change our chips when the FDA publishes a decision.

None of this is legal or medical advice.

What to do next

See every peptide's statusIs BPC-157 legal? guide

Sources

  1. FDA, Development and Approval Process: Drugs: https://www.fda.gov/drugs/development-approval-process-drugs
  2. FDA, Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act, current as of 14 May 2026: https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act
  3. FDA, FDA Authority Over Cosmetics: How Cosmetics Are Not FDA-Approved, but Are FDA-Regulated: https://www.fda.gov/cosmetics/laws-regulations/fda-authority-over-cosmetics-how-cosmetics-are-not-fda-approved-are-fda-regulated
  4. Drugs@FDA, searched through openFDA for BPC-157, GHK-Cu (also as copper tripeptide and prezatide) and TB-500 (also as thymosin beta-4): no approved product, 2 Nov 2026: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
  5. Peptide Chooser, FDA warning letters to peptide sellers, compounders and online clinics, checked 2 Nov 2026
  6. FDA, Compounding and the FDA: Questions and Answers: https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
  7. FDA, Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks, current as of 22 Apr 2026: https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
  8. FDA, FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize: https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
  9. FDA Briefing Document, Pharmacy Compounding Advisory Committee meeting, 23 and 24 Jul 2026 (BPC-157, TB-500, MOTS-c, epitalon): https://www.fda.gov/media/193342/download